Fremanezumab (Ajovy) cut monthly migraine days in children and adolescents with episodic migraine, according to the SPACE ...

For the first time in 30 years, a new drug class known as the CGRP-Antagonists (calcitonin gene-related peptide) has emerged. These medications are proving to be highly effective for migraine ...

The following is a summary of “A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide ...

The leading Migraine Companies such as ​ Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity ...

The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting CGRP for many sufferers, but Lundbeck thinks there is still room for new approaches.

Qulipta (atogepant) has become the only drug in the CGRP inhibitor class approved for prophylactic use across the spectrum of migraine, including people who experience both episodic and chronic ...

“In addition, since these drugs act by different mechanisms, it is likely that telcagepant and other CGRP receptor antagonists will help some patients who are not helped by triptans,” says Russ ...

Instead, Qulipta belongs to a group of drugs called calcitonin gene-related peptide (CGRP) antagonists. Qulipta helps prevent migraine episodes, while triptans help treat migraine episodes.

The FDA has granted marketing authorization to CT-132, an adjunctive, prescription digital therapeutic for the preventive ...